• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Port delivery system with ranibizumab (Susvimo) recall- What does it mean to the retina specialists.雷珠单抗（Susvimo）眼内注射递送系统召回——这对视网膜专家意味着什么。
Int J Retina Vitreous. 2023 Jan 30;9(1):6. doi: 10.1186/s40942-023-00446-z.
2
Ranibizumab Injection (Susvimo) Implant Septum Dislodgement in a Patient With Neovascular Age-Related Macular Degeneration.雷珠单抗注射液（Susvimo）植入物隔膜移位在一名新生血管性年龄相关性黄斑变性患者中的病例报告
JAMA Ophthalmol. 2022 Aug 1;140(8):832. doi: 10.1001/jamaophthalmol.2022.2495.
3
The Port Delivery System with ranibizumab: a new paradigm for long-acting retinal drug delivery.雷珠单抗玻璃体腔内注射给药系统：长效视网膜药物递送的新模式。
Drug Deliv. 2022 Dec;29(1):1326-1334. doi: 10.1080/10717544.2022.2069301.
4
A ranibizumab ocular implant (Susvimo) for age-related macular degeneration.一种用于年龄相关性黄斑变性的雷珠单抗眼内植入剂（Susvimo）。
Med Lett Drugs Ther. 2022 May 2;64(1649):71-72.
5
In-vitro characterization of ranibizumab release from the Port Delivery System.从 Port Delivery System 中释放雷珠单抗的体外特性分析。
J Control Release. 2022 May;345:101-107. doi: 10.1016/j.jconrel.2022.03.005. Epub 2022 Mar 4.
6
Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.阿柏西普、贝伐单抗和雷珠单抗治疗糖尿病性黄斑水肿的比较：数据外推至临床实践
JAMA Ophthalmol. 2016 Jan;134(1):95-9. doi: 10.1001/jamaophthalmol.2015.4110.
7
Evaluation of Port Delivery System with ranibizumab for the treatment of neovascular age-related macular degeneration.雷珠单抗眼内注射给药系统治疗新生血管性年龄相关性黄斑变性的疗效评估
Ther Deliv. 2021 Mar;12(3):191-200. doi: 10.4155/tde-2020-0132. Epub 2021 Mar 1.
8
Therapeutic Potential of the Ranibizumab Port Delivery System in the Treatment of AMD: Evidence to Date.雷珠单抗眼内植入给药系统治疗年龄相关性黄斑变性的潜在疗效：迄今证据
Clin Ophthalmol. 2020 May 19;14:1349-1355. doi: 10.2147/OPTH.S194234. eCollection 2020.
9
Theoretical Insights into the Retinal Dynamics of Vascular Endothelial Growth Factor in Patients Treated with Ranibizumab, Based on an Ocular Pharmacokinetic/Pharmacodynamic Model.基于眼药代动力学/药效动力学模型的抗血管内皮生长因子药物Ranibizumab 治疗患者视网膜动态的理论见解。
Mol Pharm. 2018 Jul 2;15(7):2770-2784. doi: 10.1021/acs.molpharmaceut.8b00280. Epub 2018 May 29.
10
Long-Term Stability of Anti-Vascular Endothelial Growth Factor (a-VEGF) Biologics Under Physiologically Relevant Conditions and Its Impact on the Development of Long-Acting Delivery Systems.在生理相关条件下抗血管内皮生长因子（a-VEGF）生物制剂的长期稳定性及其对长效递药系统发展的影响。
J Pharm Sci. 2021 Feb;110(2):860-870. doi: 10.1016/j.xphs.2020.09.043. Epub 2020 Oct 5.

引用本文的文献

1
Beyond the injection: delivery systems reshaping retinal disease management.注射之外：重塑视网膜疾病管理的递送系统
Expert Opin Pharmacother. 2025 Jun;26(8):939-952. doi: 10.1080/14656566.2025.2496424. Epub 2025 May 11.
2
Nonclinical study of ixo-vec gene therapy for nAMD supports efficacy for a human dose of 6E10 vg/eye and staggered dosing of fellow eyes.ixovec基因疗法治疗湿性年龄相关性黄斑变性的非临床研究支持6×10¹⁰vg/眼的人体剂量及对侧眼的交错给药方案的疗效。
Mol Ther Methods Clin Dev. 2025 Feb 10;33(1):101430. doi: 10.1016/j.omtm.2025.101430. eCollection 2025 Mar 13.
3
Intravitreal therapy-success stories and challenges.玻璃体内注射疗法——成功案例与挑战
Wien Med Wochenschr. 2025 May;175(7-8):162-174. doi: 10.1007/s10354-024-01070-8. Epub 2025 Mar 3.
4
Dry and neovascular "wet" age-related macular degeneration: Upcoming therapies.干性和新生血管性“湿性”年龄相关性黄斑变性：即将出现的疗法。
Indian J Ophthalmol. 2025 Jan 1;73(Suppl 1):S55-S65. doi: 10.4103/IJO.IJO_1120_24. Epub 2024 Oct 25.
5
Advances in ophthalmic therapeutic delivery: A comprehensive overview of present and future directions.眼科治疗药物传递的新进展：当前和未来方向的全面综述。
Surv Ophthalmol. 2024 Nov-Dec;69(6):967-983. doi: 10.1016/j.survophthal.2024.07.002. Epub 2024 Jul 8.
6
Greener intravitreal injections: a narrative review.更环保的玻璃体内注射：叙述性综述。
Eye (Lond). 2024 Oct;38(15):2874-2879. doi: 10.1038/s41433-024-03185-z. Epub 2024 Jun 24.
7
Vascular Endothelial Growth Factor C and D Signaling Pathways as Potential Targets for the Treatment of Neovascular Age-Related Macular Degeneration: A Narrative Review.血管内皮生长因子C和D信号通路作为治疗新生血管性年龄相关性黄斑变性的潜在靶点：一项叙述性综述
Ophthalmol Ther. 2024 Jul;13(7):1857-1875. doi: 10.1007/s40123-024-00973-4. Epub 2024 Jun 1.
8
Seeing the Future: A Review of Ocular Therapy.展望未来：眼部治疗综述
Bioengineering (Basel). 2024 Feb 13;11(2):179. doi: 10.3390/bioengineering11020179.
9
Intravitreal Anti-Vascular Endothelial Growth Factor Therapies for Retinal Disorders.用于视网膜疾病的玻璃体内抗血管内皮生长因子疗法
Pharmaceuticals (Basel). 2023 Aug 11;16(8):1140. doi: 10.3390/ph16081140.

本文引用的文献

1
The Port Delivery System with ranibizumab-journey of mitigating vitreous hemorrhage.雷珠单抗眼内注射递送系统——减轻玻璃体积血的历程
Eye (Lond). 2022 Mar;36(3):488-489. doi: 10.1038/s41433-021-01830-5. Epub 2021 Oct 29.
2
Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration.[研究名称] 研究：采用雷珠单抗的输送系统治疗新生血管性年龄相关性黄斑变性的随机 3 期临床试验。
Ophthalmology. 2022 Mar;129(3):295-307. doi: 10.1016/j.ophtha.2021.09.016. Epub 2021 Sep 29.
3
End-of-Study Results for the Ladder Phase 2 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration.抗 VEGF 药物 PORT 研究的 Ladder 阶段 2 试验终点结果：用于新生血管性年龄相关性黄斑变性的雷珠单抗经 PORT 给药系统给药
Ophthalmol Retina. 2021 Aug;5(8):775-787. doi: 10.1016/j.oret.2020.11.004. Epub 2020 Nov 18.
4
Brolucizumab and immunogenicity.布罗鲁单抗与免疫原性。
Eye (Lond). 2020 Oct;34(10):1726-1728. doi: 10.1038/s41433-020-0853-9. Epub 2020 Apr 6.
5
Ranibizumab port delivery system (RPDS): realising long awaited dream of prolonged VEGF suppression.雷珠单抗玻璃体内植入给药系统（RPDS）：实现了长期以来对延长血管内皮生长因子抑制作用的梦想。
Eye (Lond). 2020 Mar;34(3):422-423. doi: 10.1038/s41433-019-0479-y. Epub 2019 Jun 5.

Port delivery system with ranibizumab (Susvimo) recall- What does it mean to the retina specialists.

作者信息

Sharma Ashish, Khanani Arshad M, Parachuri Nikulaa, Kumar Nilesh, Bandello Francesco, Kuppermann Baruch D

机构信息

Lotus Eye Hospital and Institute, Avinashi Road, Coimbatore, 641014, TN, India.

Sierra Eye Associates, The University of Nevada, Reno School of Medicine, NV, Reno, USA.

出版信息

Int J Retina Vitreous. 2023 Jan 30;9(1):6. doi: 10.1186/s40942-023-00446-z.

DOI:10.1186/s40942-023-00446-z
PMID:36717931
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9887765/
Abstract
摘要